Table 1.

Patients’ characteristics.

Patients (n)	236
Median age (range)	56 years (range 19–74 years)
Gender	M/F = 139/97
Diagnosis  − Acute leukemia/MDS  − Lymphoproliferative disease  − Chronic myeloproliferative   disease  − Aplasia	− 148 (63%)  − 24 (10%)  − 52 (22%)  − 12 (5%)
Disease status before HCT  − Complete remission  − Stable disease  − Progressive disease  − HCST frontline	− 114 (48%)  − 97 (41%)  − 23 (10%)  − 4 (1%)
Conditioning regimen  − Myeloablative  − Reduced intensity  − CTX	− 153 (64%)  − 83 (35%)  − 1 (4%)
Donor  − MUD 7/8  − MUD 8/8  − SIB  − HAPLO  − CB	− 41 (17%)  − 86 (36%)  − 38 (16%)  − 68 (30%)  − 3 (1%)
GvHD prophylaxis  − CSA, CTX, MMF  − CSA, CTX, MTX, ATG	− 232 (98%)  − 4 (2%)
CD34+ cell median (range)	5.9 × 106/kg (1.6–15)
Acute GvHD grade >/=2	57 (24%)
Chronic GvHD grade >/=2	23 (10%)
Presence of anti HLA antibodies	29 (12%)

CTX, cyclophosphamide; CSA, cyclosporine; MMF, mycophenolic acid; MTX, methotrexate; ATG, anti-thymocyte globulin.